FT
FTRE.US Fortrea Holdings Inc.
- Market cap
- USD 1.95B
- P/E
- -
- P/B
- 3.64x
- ROE
- -9.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is FTRE.US undervalued?
Graham numberThe Graham number of Fortrea Holdings Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fortrea Holdings Inc. fundamental analysis
No fundamental analysis for Fortrea Holdings Inc. yet.
Fortrea Holdings Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I th…
Full company profileFortrea Holdings Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fortrea Holdings Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 2.58B | 3.06B | 2.84B | 2.84B | 2.70B | 2.72B | 2.67B |
| Gross Profit | 489M | 604M | 724M | 591M | 534M | 426M | 510M |
| Operating Income | -314M | 114M | 187M | 32.0M | -162M | -30.6M | 44.1M |
| EBITDA | 222M | 303M | 281M | 137M | -64.3M | -814M | 130M |
| Net Income | -359M | 98.0M | 186M | -25.2M | -329M | -986M | -48.3M |
| EPS | -4.06 | 1.11 | 2.11 | -0.28 | -3.67 | -11 | -0.48 |
| Balance Sheet | |||||||
| Total Assets | - | 4.37B | 4.29B | 4.33B | 3.58B | 2.72B | 2.74B |
| Total Liabilities | - | 1.11B | 945M | 2.62B | 2.22B | 2.15B | 2.21B |
| Shareholders' Equity | - | 3.26B | 3.34B | 1.71B | 1.36B | 564M | 532M |
| Cash & Short-term Investments | - | 94.6M | 112M | 109M | 119M | 175M | 221M |
| Total Debt | - | 77.2M | 63.4M | 1.67B | 1.20B | 1.12B | 1.12B |
| Cash Flow | |||||||
| Operating Cash Flow | 201M | 170M | 82.7M | 168M | 263M | 114M | 36.4M |
| Capital Expenditure | 24.0M | 26.5M | 54.4M | 40.3M | 25.5M | 25.2M | 33.7M |
| Free Cash Flow | 177M | 143M | 28.3M | 128M | 237M | 88.3M | 2.67M |
| Ratios | |||||||
| ROE | - | 3.0% | 5.6% | -1.5% | -24.1% | -175.0% | -9.1% |
| ROA | - | 2.2% | 4.3% | -0.6% | -9.2% | -36.3% | -1.8% |
| Net Profit Margin | -13.9% | 3.2% | 6.6% | -0.9% | -12.2% | -36.2% | -1.8% |
| Debt to Equity | - | 0.02x | 0.02x | 0.98x | 0.88x | 1.98x | 2.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Fortrea Holdings Inc. dividends
Fortrea Holdings Inc. has not paid dividends in the last 6 fiscal years.
Who owns Fortrea Holdings Inc.
- Insiders 1.21%
- Institutions 98.79%
- Public & others 0.00%
- Shares outstanding 96.5M
- Free float 95.4M
Top funds holding FTRE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 5.72M | 5.93% | -0.11% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.00M | 3.10% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.45M | 2.54% | 0.00% | Oct 2026 |
| Fidelity Value | 2.29M | 2.37% | 0.00% | Sep 2026 |
| Columbia Acorn Inst | 1.42M | 1.47% | -0.38% | Sep 2026 |
| Loomis Sayles Small Cap Growth Instl | 1.40M | 1.45% | 0.00% | Sep 2026 |
| Vanguard Small Cap Index | 1.07M | 1.11% | -1.51% | Sep 2026 |
| Fidelity Small Cap Index | 1.06M | 1.10% | +0.16% | Aug 2026 |
| iShares Russell 2000 Value ETF | 908K | 0.94% | 0.00% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 866K | 0.90% | -0.05% | Oct 2026 |
| Invesco S&P SmallCap Momentum ETF | 833K | 0.86% | 0.00% | Oct 2026 |
| Schwab Fundamental U.S. Small CompanyETF | 796K | 0.83% | 0.00% | Oct 2026 |
| iShares S&P Small-Cap 600 Value ETF | 790K | 0.82% | 0.00% | Oct 2026 |
| CREF Total Global Stock Account R3 | 779K | 0.81% | +14.60% | Aug 2026 |
| iShares Biotechnology ETF | 734K | 0.76% | -0.19% | Oct 2026 |
| PIMCO RAE US S Instl | 726K | 0.75% | +21.43% | Jun 2026 |
| Vanguard MStar Small Cap Value Index | 697K | 0.72% | +0.81% | Sep 2026 |
| Lord Abbett Value Opportunities I | 602K | 0.62% | 0.00% | Aug 2026 |
| Lord Abbett Small Cap Value A | 596K | 0.62% | -0.65% | Aug 2026 |
| Fidelity Value Strategies | 566K | 0.59% | 0.00% | Sep 2026 |
Top institutions holding FTRE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 15.8M | 16.37% | +4.27% | Jun 2026 |
| The Goldman Sachs Group Inc | 8.41M | 8.72% | +3.90% | Jun 2026 |
| Sessa Capital, L.P | 4.59M | 4.76% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.18M | 4.33% | +3.54% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.82M | 3.96% | +3.24% | Jun 2026 |
| State Street Corp | 3.78M | 3.92% | -7.91% | Jun 2026 |
| FMR Inc | 3.65M | 3.78% | +193.13% | Jun 2026 |
| Corvex Management LP | 2.99M | 3.10% | -35.65% | Jun 2026 |
| AQR Capital Management LLC | 2.98M | 3.09% | -9.64% | Jun 2026 |
| Geode Capital Management, LLC | 2.55M | 2.64% | +7.62% | Jun 2026 |
| Charles Schwab Investment Management Inc | 2.49M | 2.58% | -22.39% | Jun 2026 |
| Loomis, Sayles & Company LP | 2.44M | 2.53% | +33.89% | Jun 2026 |
| Wellington Management Company LLP | 2.38M | 2.47% | 0.00% | Jun 2026 |
| Park West Asset Management LLC | 2.11M | 2.18% | -6.70% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.09M | 2.17% | -8.86% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.01M | 2.08% | +21.62% | Sep 2026 |
| Ameriprise Financial Inc | 1.72M | 1.78% | +8.80% | Jun 2026 |
| Nuveen, LLC | 1.42M | 1.47% | +32.24% | Jun 2026 |
| Deutsche Bank AG | 1.40M | 1.45% | -45.62% | Jun 2026 |
| MetLife Investment Management, LLC | 1.36M | 1.41% | -24.54% | Jun 2026 |
Fortrea Holdings Inc. company profile
- Company name
- Fortrea Holdings Inc.
- Ticker
- FTRE.US
- Exchange
- USA Stocks
- Listed since
- Jul 3, 2023
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 14,000
- Fiscal year end
- December
- Address
- 8 Moore Drive, Durham, NC, United States, 27713
- Phone
- 877 495 0816
- Website
- fortrea.com
About Fortrea Holdings Inc.
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Fortrea Holdings Inc. management
10- Mr. Anshul ThakralCEO & Director · born 1978
- Mr. Mark A. MoraisCOO & President of Clinical Services · born 1977
- Ms. Jill McConnellExecutive Officer · born 1974
- Mr. Drayton VirklerPresident & Chief Commercial Officer
- Mr. Jason F. KnoblauchChief Financial Officer · born 1981
- Ms. Carrie RussellVP of Accounting & Chief Accounting Officer
- Mr. Alejandro Martinez GalindoChief Information Officer
- Mr. Dave CooperChief Administrative Officer
- Ms. Tracy H. KrummeSenior VP of Investor Relations · born 1968
- Ms. Agnieszka M. Gallagher J.D.General Counsel & Corporate Secretary · born 1974